Meeting
2019 ASCO Annual Meeting
Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.
Presenter
Joseph A. Sparano, MD
Montefiore Medical Center, Albert Einstein College of Medicine, Albert Einstein Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT00310180.
Citation
J Clin Oncol 37, 2019 (suppl; abstr 503)
DOI
10.1200/JCO.2019.37.15_suppl.503
Abstract #
503
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2021 ASCO Annual Meeting
Validation of the RSClin risk calculator using the National Cancer Database (NCDB).
Speaker: Frederick Howard
Speaker: Nazli Dizman, MD
Videos & Slides
2021 ASCO Annual Meeting
Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial.
Speaker: Oleg Gluz, MD
Speaker: Josep Tabernero, MD, PhD